The introduction of imatinib mesylate (IM) has revolutionized the treatment of chronic
myeloid leukemia (CML). Although experience is too limited to permit evidence-based …

Imatinib has revolutionized drug therapy of chronic myeloid leukemia (CML). Preclinical
studies were promising but the results of clinical trials by far exceeded expectations …

Summary The Bcr-Abl tyrosine kinase oncogene causes chronic myelogenous leukemia
(CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) …

Abstract The amphetamine derivative (±)-3, 4-methylenedioxymethamphetamine (MDMA,
ecstasy) is a popular recreational drug among young people, particularly those involved in …

Arsenic is a semi-metal or metalloid with two biologically important oxidation states, As (III)
and As (V). As (III), in particular, reacts with closely spaced protein thiols, forming stable …

Imatinib is a molecularly targeted therapy that inhibits the oncogenic fusion protein BCR-
ABL, the tyrosine kinase involved in the pathogenesis of chronic myelogenous leukemia …

Arsenic had been used in treating malignancies from the 18th to mid-20th century. In the
past 3 decades, arsenic was revived and shown to be able to induce complete remission …

Abstract Treatment with LAQ824 (Novartis Pharmaceutical, Inc.), a cinnamyl hydroxamic
acid analogue inhibitor of histone deacetylases, depleted the mRNA and protein expression …

Arsenic trioxide has shown great promise in the treatment of patients with relapsed or
refractory acute promyelocytic leukemia (APL). In clinical trials, arsenic trioxide induces …

The most common mechanism of relapse for CML patients treated with Imatinib is the
appearance of point mutations in the BCR-ABL oncogene that confer resistance to this drug …